Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

Impact · against what's priced in

Cellectis reports highly positive clinical signals for lasme-cel and eti-cel, significantly increasing the perceived probability of success for its allogeneic CAR-T pipeline. The 100% ORR in a heavily pretreated B-ALL population and the upcoming Q4 2026 interim analysis provide concrete value-inflection catalysts.

CLLS+0.80: No priced-in read yet

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

What matters in this story

Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

What matters in this story

Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs

How each ticker is affected

Track these names every morning.

BioInvent International AB (publ) (BOVNF) Q3 2026 Earnings Call Transcript

Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?

Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?

ArriVent BioPharma's ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

What matters in this story

Next reads from the same story arc

Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

What matters in this story

Next reads from the same story arc

Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs

How each ticker is affected

Track these names every morning.

BioInvent International AB (publ) (BOVNF) Q3 2026 Earnings Call Transcript

Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?

Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?

ArriVent BioPharma's ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study